<DOC>
	<DOC>NCT01356537</DOC>
	<brief_summary>The purpose of this study is to proof increasing patient satisfaction and preservation of quality of life in patients with Gaucher's Disease receiving their enzyme replacement therapy with VPRIV (Velaglucerase alfa)at their home setting compared to receiving the infusions at the clinic or at doctor's practice.</brief_summary>
	<brief_title>Home Therapy With VPRIV in Gaucher's Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Male or female patients with a confirmed diagnosis of Gaucher disease type 1 Age&gt; 2 years patients who have at least 3 infusions (6 weeks) at least 5year or 56 infusions (1012 weeks) at 2 to 4year patients have received VPRIV ® and tolerate well The patient is compliant, the previous VPRIV ® infusions were / performed approximately every 2 weeks in the center during office visits The patient was already before inclusion in this study for a home infusion therapy and has consented to (or their legal representative) The patient / be lawful. Representative has consented in writing to participate in this study. Exclusion criteria: • The patient is participating in a clinical trial with a medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>